Diffuse alveolar hemorrhage after hematopoietic cell transplantation- response to treatments and risk factors for mortality

Diffuse alveolar hemorrhage (DAH) is a life-threatening complication of hematopoietic cellular therapy (HCT). This study aimed to evaluate the effect of DAH treatments on outcomes using data from consecutive HCT patients clinically diagnosed with DAH from 3 institutions between January 2018-August 2022. Endpoints included sustained complete response (sCR) defined as bleeding cessation without recurrent bleeding, and non-relapse mortality (NRM). Forty children developed DAH at a median of 56.5 days post-HCT (range 1-760). Thirty-five (88%) had at least one concurrent endothelial disorder, including transplant-associated thrombotic microangiopathy (n=30), sinusoidal obstructive syndrome (n=19), or acute graft versus host disease (n=10). Fifty percent had a concurrent pulmonary infection at the time of DAH. Common treatments included steroids (n=17, 25% sCR), inhaled tranexamic acid (INH TXA,n=26, 48% sCR), and inhaled recombinant activated factor VII (INH fVIIa, n=10, 73% sCR). NRM was 56% 100 days after first pulmonary bleed and 70% at 1 year. Steroid treatment was associated with increased risk of NRM (HR 2.25 95% CI 1.07-4.71, p=0.03), while treatment with INH TXA (HR 0.43, 95% CI 0.19- 0.96, p=0.04) and INH fVIIa (HR 0.22, 95% CI 0.07-0.62, p=0.005) were associated with decreased risk of NRM. Prospective studies are warranted to validate these findings.

[1]  M. Qayed,et al.  Prospective Study of Allogeneic Pediatric Transplant Associated Thrombotic Microangiopathy-Novel Prognostic Markers, Biologic Interaction and Outcomes , 2023, Transplantation and Cellular Therapy.

[2]  S. McGovern,et al.  Diffuse alveolar hemorrhage: An underreported complication of transplant associated thrombotic microangiopathy , 2022, Bone Marrow Transplantation.

[3]  K. Williams Noninfectious complications of hematopoietic cell transplantation. , 2021, Hematology. American Society of Hematology. Education Program.

[4]  P. Lenting,et al.  Vascular Endothelial Damage in the Pathogenesis of Organ Injury in Severe COVID-19 , 2021, Arteriosclerosis, Thrombosis, and Vascular Biology.

[5]  Yu-Hong Chen,et al.  Risk factors and outcomes of diffuse alveolar haemorrhage after allogeneic haematopoietic stem cell transplantation , 2021, Bone Marrow Transplantation.

[6]  A. Niven,et al.  Epidemiology, Risk Factors and Outcomes of Diffuse Alveolar Hemorrhage after Hematopoietic Stem Cell Transplantation. , 2021, Chest.

[7]  Ranjit S. Chima,et al.  A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant. , 2020, Blood advances.

[8]  S. Matalon,et al.  Reactive species generated by heme impair alveolar epithelial sodium channel function in acute respiratory distress syndrome , 2020, Redox biology.

[9]  Lindsay Schmees,et al.  Inhaled Tranexamic Acid As a Novel Treatment for Pulmonary Hemorrhage in Critically Ill Pediatric Patients: An Observational Study , 2020, Critical care explorations.

[10]  J. Kurtzberg,et al.  Pulmonary Complications in Pediatric and Adolescent Patients Following Allogeneic Hematopoietic Cell Transplantation. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[11]  K. Matthay,et al.  Risk factors for transplant-associated thrombotic microangiopathy following autologous hematopoietic cell transplantation in high-risk neuroblastoma. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  L. Lehmann,et al.  Thrombotic Microangiopathy Following Pediatric Autologous Hematopoietic Cell Transplantation: A Report of Significant End-Organ Dysfunction in Eculizumab-Treated Survivors. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  Gali Epstein Shochet,et al.  Inhaled Tranexamic Acid for Hemoptysis Treatment: A Randomized Controlled Trial , 2018, Chest.

[14]  S. Miescher,et al.  Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles. , 2018, JCI insight.

[15]  K. Myers,et al.  High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma , 2018, Bone Marrow Transplantation.

[16]  Madeline Y Mayday,et al.  Pulmonary Metagenomic Sequencing Suggests Missed Infections in Immunocompromised Children , 2018, bioRxiv.

[17]  D. Janz,et al.  Cell-free hemoglobin: a novel mediator of acute lung injury. , 2016, American journal of physiology. Lung cellular and molecular physiology.

[18]  J. Park Diffuse alveolar hemorrhage and recombinant factor VIIa treatment in pediatric patients , 2016, Korean journal of pediatrics.

[19]  Mohammed S Alshahrani,et al.  Pilot trial of a novel two-step therapy protocol using nebulized tranexamic acid and recombinant factor VIIa in children with intractable diffuse alveolar hemorrhage , 2015, Annals of Saudi medicine.

[20]  Byoung-ju Kim,et al.  Intrapulmonary Recombinant Factor VIIa for Diffuse Alveolar Hemorrhage in Children , 2015, Pediatrics.

[21]  Ranjit S. Chima,et al.  Pulmonary arterial hypertension in pediatric patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[22]  J. Ryu Orphan Lung Diseases , 2011, Seminars in Respiratory and Critical Care Medicine.

[23]  Allen R. Chen,et al.  Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[24]  B. Savani,et al.  Recombinant factor VIIa to treat diffuse alveolar hemorrhage following allogeneic stem cell transplantation. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[25]  H. Sengeløv,et al.  Successful pulmonary administration of activated recombinant factor VII in diffuse alveolar hemorrhage , 2006, Critical care.

[26]  D. Weisdorf,et al.  Diffuse alveolar hemorrhage (DAH) and infection associated alveolar hemorrhage (IAH) following hematopoietic stem-cell transplantation: Related and high risk clinical syndromes with poor response to high-dose corticosteroids , 2006 .

[27]  A. Sanabria,et al.  Randomized controlled trial. , 2005, World journal of surgery.

[28]  J. Fortenberry,et al.  Diffuse alveolar hemorrhage in pediatric hematopoietic cell transplant patients. , 2002, Pediatrics.

[29]  I. Lewis,et al.  Increasing incidence of diffuse alveolar hemorrhage following allogeneic bone marrow transplantation: cryptic etiology and uncertain therapy , 2000, Bone Marrow Transplantation.

[30]  A. Raptis,et al.  High-dose corticosteroid therapy for diffuse alveolar hemorrhage in allogeneic bone marrow stem cell transplant recipients , 1999, Bone Marrow Transplantation.

[31]  K. Bradstock,et al.  Diffuse alveolar haemorrhage associated with microangiopathy after allogeneic bone marrow transplantation. , 1995, Bone marrow transplantation.

[32]  J. Armitage,et al.  Diffuse alveolar hemorrhage in autologous bone marrow transplant recipients. , 1991, The American journal of medicine.

[33]  S. Horning,et al.  Corticosteroid therapy for diffuse alveolar hemorrhage in autologous bone marrow transplant recipients. , 1991, Annals of internal medicine.

[34]  Gerhard Nahler Observational Study , 2018 .

[35]  J. Álvarez-Sala,et al.  [Alveolar hemorrhage]. , 1990, Revista clinica espanola.